{"id":27634,"date":"2025-06-24T16:46:21","date_gmt":"2025-06-24T13:46:21","guid":{"rendered":"https:\/\/www.clinica-sante.com\/ro\/analize-fara-categorie\/solid-tumor-panel-panel-genetic-somatic-tumori-solide-149-gene-multiorgan\/"},"modified":"2026-07-02T12:32:58","modified_gmt":"2026-07-02T09:32:58","slug":"solid-tumor-panel-panel-genetic-somatic-tumori-solide-149-gene-multiorgan","status":"publish","type":"product","link":"https:\/\/www.clinica-sante.com\/ro\/analize-oncogenetica\/solid-tumor-panel-panel-genetic-somatic-tumori-solide-149-gene-multiorgan\/","title":{"rendered":"Solid tumor panel-Panel genetic somatic tumori solide"},"content":{"rendered":"

Solid Tumor Panel (CENTOGENE)<\/strong> este un panel oncologic amplu bazat pe tehnologie Next Generation Sequencing<\/strong>, destinat profil\u0103rii moleculare a tumorilor solide.<\/p>\n

Analiza investigheaz\u0103 muta\u021bii somatice (dob\u00e2ndite) ap\u0103rute \u00een celulele tumorale, implicate \u00een:<\/h3>\n
    \n
  • activarea oncogenelor,<\/li>\n
  • inactivarea genelor supresoare tumorale,<\/li>\n
  • instabilitate genomic\u0103 tumoral\u0103,<\/li>\n
  • rezisten\u021b\u0103 la tratamente oncologice.<\/li>\n<\/ul>\n

    Panelul acoper\u0103 un num\u0103r extins de gene oncologice relevante clinic \u0219i include:<\/h3>\n
      \n
    • SNV (variante punctiforme)<\/li>\n
    • Indel-uri (dele\u021bii\/inser\u021bii mici)<\/li>\n
    • CNV (varia\u021bii de num\u0103r de copii)<\/li>\n
    • regiuni hotspot oncogenice<\/li>\n
    • biomarkeri predictivi pentru terapii \u021bintite<\/li>\n<\/ul>\n

      Panelul include aproximativ:<\/h3>\n
        \n
      • ~149 gene oncologice relevante <\/strong>(num\u0103rul genelor este variabil),<\/li>\n
      • secven\u021biere complet\u0103 pentru gene selectate \u0219i regiuni hotspot pentru altele,<\/li>\n
      • variante asociate cu decizii terapeutice validate clinic.<\/li>\n<\/ul>\n

        Indica\u021bii de testare<\/h3>\n
          \n
        • Tumori solide (diagnostic recent sau confirmat histologic)<\/li>\n
        • Boal\u0103 metastatic\u0103 sau avansat\u0103<\/li>\n
        • Identificarea muta\u021biilor pentru terapii \u021bintite<\/li>\n
        • Progresie sub tratament oncologic standard<\/li>\n
        • Cazuri f\u0103r\u0103 r\u0103spuns la tratamente conven\u021bionale<\/li>\n
        • Profilare molecular\u0103 pentru medicina personalizat\u0103<\/li>\n
        • Selectarea pacien\u021bilor pentru studii clinice<\/li>\n<\/ul>\n

          Cui se adreseaz\u0103<\/h3>\n
            \n
          • Pacien\u021bilor oncologici cu tumori solide<\/li>\n
          • Medicilor oncologi medicali<\/li>\n
          • Anatomo-patologilor<\/li>\n
          • Centrelor de oncologie de precizie<\/li>\n
          • Tumor boardurilor multidisciplinare<\/li>\n<\/ul>\n

            Metodologie de testare<\/h3>\n
              \n
            • Prelevare \u021besut tumoral FFPE (bloc parafinat)<\/li>\n
            • Confirmare procent tumoral de c\u0103tre anatomopatolog<\/li>\n
            • Extrac\u021bie ADN tumoral<\/li>\n
            • Preg\u0103tire bibliotec\u0103 genomic\u0103<\/li>\n<\/ul>\n

              Secven\u021biere NGS (Illumina \/ platform\u0103 echivalent\u0103)<\/h3>\n

              Detectarea variantelor:<\/h3>\n
                \n
              • SNV<\/li>\n
              • Indel<\/li>\n
              • CNV<\/li>\n
              • Analiz\u0103 bioinformatic\u0103 \u0219i interpretare clinic\u0103<\/li>\n
              • Corelare cu baze de date oncogenetice (terapii aprobate \u0219i studii clinice)<\/li>\n<\/ul>\n

                Biomarkeri \u0219i utilitate clinic\u0103<\/h3>\n

                Testul permite identificarea de:<\/h3>\n
                  \n
                • muta\u021bii ac\u021bionabile terapeutic (targetable mutations)<\/li>\n
                • biomarkeri predictivi pentru r\u0103spuns la tratament<\/li>\n
                • muta\u021bii asociate rezisten\u021bei terapeutice<\/li>\n
                • modific\u0103ri cu valoare prognostic\u0103<\/li>\n<\/ul>\n

                  Gene frecvent incluse \u00een paneluri similare:<\/h3>\n
                    \n
                  • EGFR, KRAS, NRAS<\/li>\n
                  • BRAF<\/li>\n
                  • PIK3CA<\/li>\n
                  • TP53<\/li>\n
                  • ERBB2 (HER2)<\/li>\n
                  • ALK, ROS1, RET<\/li>\n
                  • MET, KIT<\/li>\n
                  • BRCA1\/2 (somatic)<\/li>\n<\/ul>\n

                    Beneficii \u0219i importan\u021b\u0103 clinic\u0103<\/h3>\n
                      \n
                    • Permite oncologie de precizie<\/strong> (tratament personalizat)<\/li>\n
                    • Identific\u0103 op\u021biuni de terapii \u021bintite<\/li>\n
                    • Ajut\u0103 la alegerea tratamentului optim \u00een cancer avansat<\/li>\n
                    • Ofer\u0103 informa\u021bii prognostice importante<\/li>\n
                    • Poate indica eligibilitatea pentru studii clinice<\/li>\n
                    • Optimizeaz\u0103 strategia terapeutic\u0103 multidisciplinar\u0103<\/li>\n
                    • Cre\u0219te \u0219ansa de r\u0103spuns la tratament<\/li>\n<\/ul>\n

                      Analize asociate recomandate<\/h3>\n

                      Profil molecular extins<\/h3>\n
                        \n
                      • PIK3CA muta\u021bii hotspot<\/li>\n
                      • MSI (instabilitate microsatelitar\u0103)<\/li>\n
                      • TMB (tumor mutational burden)<\/li>\n
                      • PD-L1 imunohistochimie<\/li>\n
                      • HRD \/ BRCA status<\/li>\n<\/ul>\n

                        Paneluri complementare<\/h3>\n
                          \n
                        • Cancer specific panels (colon, s\u00e2n, pulmonar etc.)<\/li>\n
                        • Liquid biopsy (ctDNA NGS)<\/li>\n
                        • Teste de rezisten\u021b\u0103 la terapii \u021bintite<\/li>\n<\/ul>\n

                          Evaluare histopatologic\u0103<\/h3>\n
                            \n
                          • Tip tumoral \u0219i grad de diferen\u021biere<\/li>\n
                          • Index proliferativ Ki-67<\/li>\n
                          • Necroz\u0103 tumoral\u0103 \/ invazie<\/li>\n<\/ul>\n

                            Prob\u0103 recoltat\u0103 \/ condi\u021bii analiz\u0103<\/h3>\n

                            \u021aesut tumoral FFPE (bloc de parafin\u0103 sau lame albe)<\/h3>\n
                              \n
                            • Con\u021binut tumoral adecvat confirmat histologic<\/li>\n
                            • Fixare standard \u00een formalin\u0103<\/li>\n
                            • Transport la temperatura camerei<\/li>\n
                            • Protejarea ADN-ului de degradare<\/li>\n
                            • Informa\u021bii clinico-patologice obligatorii pentru interpretare<\/li>\n<\/ul>\n

                              Denumiri alternative (rom\u00e2n\u0103)<\/h3>\n
                                \n
                              • Panel genomic somatic pentru tumori solide<\/li>\n
                              • Profil genetic tumoral prin NGS<\/li>\n
                              • Test genetic oncologic complet din tumor\u0103<\/li>\n
                              • Analiz\u0103 molecular\u0103 tumoral\u0103 extins\u0103<\/li>\n
                              • Panel muta\u021bii cancer solid (FFPE)<\/li>\n
                              • Secven\u021biere genomic\u0103 tumoral\u0103 NGS<\/li>\n
                              • Profilare genetic\u0103 a cancerului solid<\/li>\n
                              • Test genomic oncologic personalizat<\/li>\n
                              • Panel oncologic de precizie tumoral<\/li>\n
                              • Analiz\u0103 ADN tumoral somatic<\/li>\n<\/ul>\n

                                Particularit\u0103\u021bi ale testului<\/h3>\n

                                Solid Tumor Panel reprezint\u0103 un instrument de medicin\u0103 de precizie oncologic\u0103<\/strong>, bazat pe secven\u021biere genomic\u0103 avansat\u0103, care permite identificarea simultan\u0103 a multiplelor tipuri de alter\u0103ri somatice relevante clinic. Rezultatele contribuie direct la decizia terapeutic\u0103 \u00een tumorile solide, \u00een special \u00een stadii avansate sau metastatice.<\/p>\n","protected":false},"excerpt":{"rendered":"

                                Analiz\u0103 genomic\u0103 prin NGS<\/strong> pentru detectarea muta\u021biilor somatice \u00een tumori solide<\/strong>, utiliz\u00e2nd \u021besut tumoral FFPE. Testul identific\u0103 alter\u0103ri genetice implicate \u00een oncogenez\u0103, cu rol diagnostic, prognostic \u0219i predictiv pentru terapii \u021bintite.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"inline_featured_image":false},"product_brand":[],"product_cat":[1209,3165,2876],"product_tag":[],"class_list":["post-27634","product","type-product","status-publish","product_cat-analize","product_cat-oncogenetica","product_cat-serviciu-laborator","first","instock","sale","virtual","purchasable","product-type-simple"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t